Egalet Corporation (NASDAQ:EGLT)’s Trend Up, Especially After Decreased Shorts

April 26, 2018 - By Vivian Park

Egalet Corporation (NASDAQ:EGLT) Logo

Investors sentiment decreased to 0.47 in Q4 2017. Its down 0.11, from 0.58 in 2017Q3. It worsened, as 13 investors sold Egalet Corporation shares while 17 reduced holdings. 6 funds opened positions while 8 raised stakes. 13.62 million shares or 32.80% less from 20.27 million shares in 2017Q3 were reported.
Moreover, Atlantic Trust Gru Limited has 0% invested in Egalet Corporation (NASDAQ:EGLT). Sabby, a New Jersey-based fund reported 73,792 shares. Vanguard Group reported 1.28M shares stake. Fmr Ltd holds 767,013 shares. Morgan Stanley invested in 3,410 shares. Geode Cap Mgmt Limited owns 67,633 shares. 40,137 were accumulated by Tiverton Asset Mgmt Llc. Bnp Paribas Arbitrage owns 38 shares for 0% of their portfolio. Hightower Advsr Limited Liability Corp invested in 268,828 shares or 0% of the stock. Parallax Volatility Advisers L P holds 619,360 shares or 0% of its portfolio. Virtu Ltd Liability Co reported 0% of its portfolio in Egalet Corporation (NASDAQ:EGLT). Moreover, Northern Tru has 0% invested in Egalet Corporation (NASDAQ:EGLT). Texas-based Highland Ltd Partnership has invested 0.01% in Egalet Corporation (NASDAQ:EGLT). Moreover, Macquarie Group has 0% invested in Egalet Corporation (NASDAQ:EGLT). Advisory Svcs Net Limited Com stated it has 0% in Egalet Corporation (NASDAQ:EGLT).

The stock of Egalet Corporation (NASDAQ:EGLT) registered a decrease of 11.28% in short interest. EGLT’s total short interest was 7.26 million shares in April as published by FINRA. Its down 11.28% from 8.19M shares, reported previously. With 1.71M shares average volume, it will take short sellers 4 days to cover their EGLT’s short positions.

The stock increased 3.07% or $0.019 during the last trading session, reaching $0.644. About 136,443 shares traded. Egalet Corporation (NASDAQ:EGLT) has declined 87.31% since April 26, 2017 and is downtrending. It has underperformed by 98.86% the S&P500.

Egalet Corporation, a specialty pharmaceutical company, develops, makes, and commercializes treatments for patients with pain and other conditions. The company has market cap of $34.04 million. It has licensed three approved pain products, such as SPRIX Nasal Spray, a non-steroidal anti-inflammatory drug indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level; OXAYDO, an immediate-release oxycodone product designed to discourage abuse via snorting for the management of acute and chronic moderate to severe pain where an opioid is appropriate; and ARYMO ER, an extended-release morphine product formulated with abuse-deterrent (AD) properties for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. It currently has negative earnings. The firm is also developing Egalet-002, a Guardian Technology AD, ER, oral oxycodone formulation, which is in Phase III clinical trials for the same indication as ARYMO ER.

Egalet Corporation (NASDAQ:EGLT) Ratings Coverage

Among 3 analysts covering Egalet Corp (NASDAQ:EGLT), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. Egalet Corp has $7.0 highest and $3.5 lowest target. $3.50’s average target is 443.48% above currents $0.644 stock price. Egalet Corp had 4 analyst reports since November 8, 2017 according to SRatingsIntel. As per Thursday, November 9, the company rating was downgraded by Gabelli. As per Monday, March 12, the company rating was maintained by Cantor Fitzgerald. The stock has “Hold” rating by Stifel Nicolaus on Wednesday, January 3. The rating was maintained by Cantor Fitzgerald with “Buy” on Wednesday, November 8.

Egalet Corporation (NASDAQ:EGLT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.